AEON Biopharma, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
AEON$0.18-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
The information regarding executive compensation is incorporated by reference to the information under the caption “Executive and Director Compensation” that will be included in the AEON Biopharma, Inc. Proxy Statement for our 2026 Annual Meeting of Shareholders.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.